Cerevia

Cerevia operates at the intersection of dementia care, medical devices, neuroscience, and AI-enabled precision medicine. Its stated differentiation is a closed-loop, image-guided neuromodulation approach that combines functional MRI with AI and machine learning to personalize therapy, rather than describing a general-purpose digital health or standalone analytics product. Ladybug Sanctuary is presented as a compact, non-invasive treatment unit, with intended use across academic medical centers, neurology clinics, and memory care settings. The profile places Cerevia among emerging medical-device and therapeutics efforts using computational methods in neurological care, but does not establish market share or a defensible lead over alternatives. Its competitive position will depend on evidence for the therapy, clinical validation, practical integration into care settings, and the ability to fund trials and eventual deployment.

Cerevia’s recorded timeline points to an early-stage company founded in 2025 and a non-equity assistance milestone on May 27, 2026, with MedTech Innovator identified as the lead investor for that assistance. Separate Seed, Series A, and Series B entries have no dates or disclosed amounts and are not reflected in the structured count of one funding round, so they should be treated as unconfirmed financing signals rather than established milestones. Cerevia says it is seeking angel and venture investment to support growth and clinical trials, making clinical validation and capital access potential inflection points. The company is listed in the 1–10 employee range, with no growth history or hiring plan specified. Overall, the available facts suggest an early development trajectory, while trial progress, regulatory milestones, hiring, and commercialization remain unclear.